About Hexagon Bio
Hexagon Bio is a company based in Menlo Park (United States) founded in 2017. Hexagon Bio has raised $205.6 million across 5 funding rounds from investors including CPP Investments, SoftBank Vision Fund and The Column Group. The company has 34 employees as of December 31, 2020. Hexagon Bio offers products and services including Science Platform and Antibody Drug Conjugates. Hexagon Bio operates in a competitive market with competitors including Strand Life Sciences, Genomics, Seven Bridges Genomics, Depixus and Ingenuity Systems, among others.
- Headquarter Menlo Park, United States
- Employees 34 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hexagon Bio, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$205.6 M (USD)
in 5 rounds
-
Latest Funding Round
$77.3 M (USD), Series B
Sep 30, 2022
-
Investors
CPP Investments
& 6 more
-
Employee Count
34
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hexagon Bio
Hexagon Bio offers a comprehensive portfolio of products and services, including Science Platform and Antibody Drug Conjugates.
Platform for mining genomes and developing novel ADC payloads using computation.
Solutions for creating next-generation cancer treatments with orthogonal mechanisms.
People of Hexagon Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Hexagon Bio
Hexagon Bio has successfully raised a total of $205.6M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $77.3 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series B — $77.3M
-
First Round
First Round
(16 Jun 2017)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Series B - Hexagon Bio | Valuation |
investors |
|
| Jun, 2021 | Amount | Series B - Hexagon Bio | Valuation | Nextech Invest | |
| Sep, 2020 | Amount | Series A - Hexagon Bio | Valuation | TCG , Two Sigma Ventures |
|
Investors in Hexagon Bio
Hexagon Bio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include CPP Investments, SoftBank Vision Fund and The Column Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in US life science startups are focused on.
|
Founded Year | Domain | Location | |
|
Early-stage investments in tech sectors are managed by the firm.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in technology, life sciences, and related sectors.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hexagon Bio
Financial Statements - Hexagon Bio
Hexagon Bio Comparisons
Competitors of Hexagon Bio
Hexagon Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Strand Life Sciences, Genomics, Seven Bridges Genomics, Depixus and Ingenuity Systems, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| domain | founded_year | HQ Location |
Genomic risk assessment and prevention platform is provided.
|
|
| domain | founded_year | HQ Location |
Cloud-based platform to analyze, store, and act on genomic data.
|
|
| domain | founded_year | HQ Location |
Single-molecule genetic and epigenetic sequencing solutions are provided.
|
|
| domain | founded_year | HQ Location |
Genomic data is analyzed and interpreted via web-based applications.
|
|
| domain | founded_year | HQ Location |
New genome engineering technology is provided for treating multiple diseases.
|
Frequently Asked Questions about Hexagon Bio
Hexagon Bio was founded in 2017.
Hexagon Bio is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Hexagon Bio is a funded company, having raised a total of $205.6M across 5 funding rounds to date. The company's 1st funding round was a Series A of $47M, raised on Jun 16, 2017.
As of Dec 31, 2020, the latest employee count at Hexagon Bio is 34.
Hexagon Bio was founded in 2017 and is based in Menlo Park, United States. Operations focus on the bioinformatics sector, where tools are developed for processing microbial genome sequencing data. Researchers utilize the platform to examine sequencing outputs and pinpoint small-molecule drug candidates for therapeutic uses across various applications. Services emphasize data analysis support in biotechnology and pharmaceuticals.
Hexagon Bio's top competitors include Strand Life Sciences, Tessera Therapeutics and Phase Genomics.
Hexagon Bio offers Science Platform and Antibody Drug Conjugates.
Hexagon Bio has 7 investors. Key investors include CPP Investments, SoftBank Vision Fund, The Column Group, Two Sigma Ventures, and 8VC.